CC
TPST icon

Commodore Capital’s Tempest Therapeutics TPST Stock Holding History

Commodore Capital’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,744
Closed -$1.98M – 34
2020
Q4 		$1.98M Buy
+4,744
New +$1.64M 1.08% 27

Other funds holding TPST

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Commodore Capital's TPST Position: Q1 2021 in Review

Commodore Capital sold out of Tempest Therapeutics (TPST) in Q1 2021, closing a stake of 4,744 shares — an estimated $1.98M sold.

Commodore Capital first reported a position in TPST in Q4 2020 and held it in 1 quarter. The position peaked at $1.98M in Q4 2020. 30 funds tracked by Wall St. Rank hold TPST as of Q1 2021.

  • Commodore Capital reported no remaining Tempest Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Commodore Capital sold 4,744 Tempest Therapeutics shares in Q1 2021, an estimated $1.98M.
  • Commodore Capital first reported a position in Tempest Therapeutics in Q4 2020 and held it in 1 quarter.
  • Commodore Capital's Tempest Therapeutics position peaked at $1.98M in Q4 2020.
  • 30 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2021.

Based on Commodore Capital's 13F filing for Q1 2021, filed 17 May 2021.